Matho et al., 2015 - Google Patents
Structural and functional characterization of anti-A33 antibodies reveal a potent cross-species orthopoxviruses neutralizerMatho et al., 2015
View HTML- Document ID
- 17754330876007436893
- Author
- Matho M
- Schlossman A
- Meng X
- Benhnia M
- Kaever T
- Buller M
- Doronin K
- Parker S
- Peters B
- Crotty S
- Xiang Y
- Zajonc D
- Publication year
- Publication venue
- PLoS pathogens
External Links
Snippet
Vaccinia virus A33 is an extracellular enveloped virus (EEV)-specific type II membrane glycoprotein that is essential for efficient EEV formation and long-range viral spread within the host. A33 is a target for neutralizing antibody responses against EEV. In this study, we …
- 102000004965 antibodies 0 title abstract description 103
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Matho et al. | Structural and functional characterization of anti-A33 antibodies reveal a potent cross-species orthopoxviruses neutralizer | |
| Gilchuk et al. | Cross-neutralizing and protective human antibody specificities to poxvirus infections | |
| Murin et al. | Antibody responses to viral infections: a structural perspective across three different enveloped viruses | |
| Mucker et al. | Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates | |
| Kim et al. | An anti-Gn glycoprotein antibody from a convalescent patient potently inhibits the infection of severe fever with thrombocytopenia syndrome virus | |
| Kaever et al. | Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein | |
| Planchais et al. | Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA. 1 and BA. 2 | |
| Benhnia et al. | Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement | |
| Crowe Jr | Human antibodies for viral infections | |
| CN104892753B (en) | Antibody neutralizing human infection with H7N9 influenza A virus and application thereof | |
| Chen et al. | Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model | |
| Matho et al. | Structural and biochemical characterization of the vaccinia virus envelope protein D8 and its recognition by the antibody LA5 | |
| Kaever et al. | Linear epitopes in vaccinia virus A27 are targets of protective antibodies induced by vaccination against smallpox | |
| JP2009518320A (en) | Anti-orthopox virus recombinant polyclonal antibody | |
| Benhnia et al. | Heavily isotype-dependent protective activities of human antibodies against vaccinia virus extracellular virion antigen B5 | |
| Bullen et al. | Cross-reactive SARS-CoV-2 neutralizing antibodies from deep mining of early patient responses | |
| Benhnia et al. | Unusual features of vaccinia virus extracellular virion form neutralization resistance revealed in human antibody responses to the smallpox vaccine | |
| Su et al. | Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein | |
| Schiffner et al. | Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins | |
| Sutton et al. | Vaccine elicitation and structural basis for antibody protection against alphaviruses | |
| Sheikhi et al. | An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein | |
| US20210363195A1 (en) | Recombinant hiv env polypeptides and their use | |
| Ren et al. | Identification of mpox M1R and B6R monoclonal and bispecific antibodies that efficiently neutralize authentic mpox virus | |
| Changrob et al. | Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants | |
| Moirangthem et al. | Dual neutralization of influenza virus hemagglutinin and neuraminidase by a bispecific antibody leads to improved antiviral activity |